PDCD1 and neoplasm: The underlying mechanisms include a loss of antitumor CD4+ T cells, and an accumulation of exhausted, unconventionally activated CD8+PD-1+ T cells, which impede tumor immune surveillance and the efficacy of immunotherapy (131, 132).